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KEY MESSAGES 
 Different arm pain physiotherapy strategies have similar costs and QALYs  
 Immediate physiotherapy is more likely to be cost-effective than usual care (waiting list) physiotherapy 
 Advice to remain active is more likely to be cost-effective than advice to rest 
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ABSTRACT  
Background. Arm pain is common, costly to health services and society. Physiotherapy referral is standard 
management, and while awaiting treatment, advice is often given to rest, but the evidence base is weak. 
Objective. To assess the cost-effectiveness of advice to remain active (AA) vs advice to rest (AR); and 
immediate physiotherapy (IP) vs usual care (waiting-list) physiotherapy (UCP). 
Methods. 26-week within-trial economic evaluation (538 participants aged ≥18 years randomised to usual care 
i.e. AA(n=178), AR(n=182) or IP(n=178)). Regression analysis estimated differences in mean costs and 
Quality Adjusted Life Years (QALYs). Incremental cost-effectiveness ratios (ICERs) and cost-effectiveness 
acceptability curves were generated. Primary analysis comprised the 193 patients with complete resource use 
(UK NHS perspective) and EQ-5D data. Sensitivity analysis investigated uncertainty. 
Results. Baseline adjusted cost differences were £88[95%CI:-14,201]) AA vs AR; -£14[95%CI:-87,66]) IP vs 
UCP. Baseline adjusted QALY differences were 0.0095[95% CI:-0.0140,0.0344]) AA vs AR; 0.0143[95%CI:-
0.0077,0.0354]) IP vs UCP. There was a 71 % and 89% probability that AA (vs AR) and IP (vs UCP) were the 
most cost-effective option using a threshold of £20,000 per additional QALY. The results were robust in the 
sensitivity analysis. 
Conclusion. The difference in mean costs and mean QALYs between the competing strategies was small and 
not statistically significant. However, decision-makers may judge that IP was not shown to be any more 
effective than delayed treatment, and was no more costly than delayed physiotherapy. AA is preferable to one 
that encourages AR, as it is more effective and more likely to be cost-effective than AR. 
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INTRODUCTION 
Upper limb disorders are common in western populations.  They may arise from specific abnormalities in the 
neck or arm (e.g. tendonitis, nerve compression), but often occur in the absence of identifiable underlying 
pathology (non-specific arm pain).  They frequently cause significant disability, and therefore impose a 
substantial economic burden. In the UK, the prevalence rate of self-reported work-related upper limb disorders 
(WRULDs), from the Labour Force Survey, an annual survey of 38,000 households, was 222,000 total cases 
(case rate of 690 per 100,000 people employed) in 2015/16.1 In addition, there were 3,138,000 days lost due 
to WRULDs (representing 36% of the total number of days lost due to work related ill health from work related 
musculoskeletal disorders of 8,784,000 days).  Annual general practice consultation prevalence for upper limb 
problems amount to 467 per 10,000 registered persons (shoulder 199, hand 132, elbow 78, wrist 58); i.e. 268 
for distal upper limb specifically per 10,000 persons.2  
Early intervention in general, and early treatment by physiotherapists in particular, for common musculoskeletal 
problems such as low back pain can reduce the amount of time people are off sick and can prevent acute 
problems becoming chronic.3  In the management of low back pain, patients are advised to remain active 
because evidence from randomised controlled trials (RCTs) indicates that this improves prognosis (compared 
to the previous practice for many years of managing low back pain with bed rest).4  In contrast, patients with 
upper limb conditions are often advised to rest the arm, while awaiting physiotherapy.  Thus for example, in 
the UK, guidance from the National Health Service (NHS) website recommends that for repetitive strain injury 
and tennis elbow, it is important to rest the injured limb, and/or to stop doing the activity that is causing the 
problem.5, 6 However, we can identify no published evidence to support this advice.  
Written information providing evidence-based advice to patients (The Back Book) has proved effective in 
promoting positive beliefs and contributing to better clinical outcomes from back pain.7 As distal arm pain 
(affecting the elbow, forearm, writs or hand) shares many risk factors with back pain, it seemed plausible that 
it might benefit from a similar approach.  It was possible also that prognosis could be improved by earlier 
delivery of physiotherapy, an approach that has been advocated, but with little supporting evidence.3  
An RCT (the ARM trial) was therefore carried out to compare the effectiveness of different approaches to the 
management of distal arm pain in reducing long term disability. The trial found among participants awaiting 
physiotherapy, advice to remain active (AA) was superior to advice to rest (AR) in producing a long-term 
reduction in arm pain and disability; but that outcomes following immediate physiotherapy (IP) were no better 
than from usual care (waiting-list) physiotherapy).8  It does not necessarily follow, however, that AA pending 
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usual care (waiting-list) physiotherapy is the most cost-effective form of clinical management. To compare the 
cost-effectiveness of the three approaches to treatment (AA, AR and IP), we conducted a parallel economic 
evaluation, which we report in this paper. 
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METHODS 
Subjects, study design and interventions 
The methods of the ARM trial have been described in detail elsewhere.8,9  The flow of participants through the 
trial is summarised as a flow chart (supplementary Figure S1), but briefly, the study was an RCT conducted in 
the UK setting in which 538 adults (aged 18 years and older) who had been newly referred to physiotherapy 
departments with an episode of distal arm pain. Patients were potentially eligible for study and randomisation 
if they were newly referred for out-patient physiotherapy with distal arm pain or disability, and were aged 
≥18yrs at the time of referral.  They were excluded, however, if: they had received physiotherapy for distal 
arm pain within the past twelve months. Study participants were randomly assigned to receive one of three 
interventions: 
Usual care (waiting-list) physiotherapy (UCP) with advice to remain active (AA)—The advice was 
delivered through a booklet advocating maintained activity and a self-management approach as generally 
helpful in promoting more rapid recovery (and earlier return to work). 
Usual care (waiting-list) physiotherapy (UCP) with advice to rest (AR)—Participants in this arm of the trial 
received an advice booklet advocating rest and avoidance of activities that might aggravate symptoms. 
Participants assigned to the two UCP interventions (AA and AR) were invited to attend physiotherapy, as per 
usual clinical care, after a period on a waiting list (median ICR days: 45 (34·5-63·5) and 47 (35-63) for AA and 
AR respectively).8 
Immediate physiotherapy (IP)—Participants in this arm of the trial received an out-patient appointment to 
attend physiotherapy at their earliest convenience, within a few days following randomisation. 
Data collection 
Participants completed questionnaires including the EQ-5D-3L health status instrument,10,11 at baseline, and 
6, 13 and 26 weeks post-randomisation. Over the same period they recorded use of health care related to 
elbow, forearm, wrist, and hand pain— including contacts with providers of primary and secondary care and 
hospital stays, both within the NHS and in the private sector.  Non-responders received a reminder 
questionnaire after two weeks.  After a further two weeks, non-responders were followed up by telephone, and 
were asked brief questions on the primary outcome only, using a standardised pro forma. 
Costs 
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Standard unit costs from published UK sources were used to value the NHS resources that were used (for the 
primary analysis conducted from a UK NHS cost perspective and time horizon of 26 weeks), and information 
from the published literature to value the care obtained from private providers (Table 1) (for a secondary 
analysis conducted from a NHS plus private health care perspective).  Resource use included primary care 
visits (general practitioner, practice nurse, community physiotherapist, complementary therapist and other 
community health care professionals), hospital outpatient visits and inpatient stays. These aforementioned 
types of costs to the NHS were calculated using the Personal and Social Service Research Unit (PSSRU) 
costs12 for primary care contacts and the NHS Reference Costs for outpatient appointments and inpatient 
hospitalisations.13  Private care was costed using estimates of treatments from published UK studies.14,15  All 
costs were expressed in UK pounds sterling (£) at 2013/14 prices.  Advice leaflet production costs (applied to 
the AA and AR groups) were estimated directly from the trial finance documents.  
Health outcomes 
The effects of the three treatments were expressed as gain in quality-adjusted life years (QALYs) based on 
the EQ-5D10,11 generic preference-based measure of health-related quality of life data collected in the trial. 
Published UK general population tariffs were used to assign each participant a health state utility weight for 
the EQ-5D11 at baseline and at each follow-up time point. QALYs between baseline and 26 weeks were 
calculated for each participant using the area under the curve (AUC) method (i.e. implemented by summing 
the areas of the geometrical shapes obtained by linearly interpolating between utility scores over the study 
period).16 
It was not necessary to discount the costs and outcomes, as the time horizon of the study was less than one 
year. All analyses were carried out using STATA 14.0 and Microsoft Excel. 
Economic evaluation analytical approach - Cost-utility analysis 
The primary economic analysis was conducted on an intention-to-treat basis and was performed for 
participants with complete data on resource use and health utilities at baseline, 6, 13, and 26 weeks follow-up 
from the NHS cost perspective. Complete resource use and EQ-5D data from questionnaires was available 
for 193 patients: AA (n=53), AR (n=60), and IP (n=80). Generalised linear regression analyses were used to 
estimate the differences (and associated 95% CIs) in mean total costs and differences in mean total QALYs 
comparing: i) AA vs AR, and ii) IP vs v UCP per patient, while adjusting for baseline differences in cost, 
utility and other patient characteristics (e.g. age, gender, employment status, disability – based on a modified 
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DASH, Disabilities of the Arm Shoulder and Hand score).  In addition, a secondary analysis was conducted 
from the perspective of both NHS and private health care perspectives. 
A generalised linear model, with a γ family distribution and a log link function, was specified to account for 
skewed cost data. For QALYs, a Gaussian family distribution and an identity link function was used. Cost-
effectiveness acceptability curves (CEACs) were constructed by non-parametric bootstrapping, using 1,000 
replications of each incremental cost-effectiveness ratio (ICER) and the net monetary benefit framework, to 
determine the probability of the alternative interventions being considered cost-effective at different willingness 
to pay (WTP) per QALY values (a range of £20,000-£30,000 per QALY was used, as these are commonly 
applied ceiling ratios in the UK).  
We performed two sensitivity analyses to explore the impact on the results of uncertainty in assumptions or 
estimates made.  First, we imputed missing QALY and cost data (assumed to be missing at random)17 using 
chained equations (i.e., 193 out of 538 patients with complete; 345 patients with incomplete data, so imputed) 
including age, sex, baseline mDASH, baseline EQ-5D, baseline work status, and baseline cost as predictors, 
covariates.  Secondly, we excluded cost “outliers” (defined as participants whose costs exceeded £1,000 - 
more than five times the median cost).  
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RESULTS 
Participants 
In the primary economic analysis, the baseline mean (SD) age of participants was 53 (13) years, and 37% 
were male.  The percentage in employment was 64% and the baseline mean (SD) EQ-5D and mDASH scores 
were 0.708 (0.188) and 5.8 (2.7) respectively.  
Resource use and cost 
Table 2 presents disaggregated data on mean resource use and (unadjusted) total costs—for both NHS and 
private health care over 26 weeks.  The mean (unadjusted) total NHS costs per participant were estimated to 
be AA £309.91 (SD £321.45), AR £223.15 (SD £225.39), and IP £221.46 (SD £220.54).  Whereas NHS costs 
were generally similar between AR and IP, AA participants used more NHS primary care and secondary care 
services.  These additional costs arose from extra community physiotherapist visits, CT visits, and hospital 
physiotherapist and rheumatology outpatient visits. All other resource use was similar across the three groups.  
The mean private health care costs were also highest in the AA group (£78.85, SD £194.35) as compared with 
AR (£31.25, SD £97.22) and IP (£18.93, SD £102.31). 
Health outcomes 
Table 3 shows the EQ-5D scores and (raw unadjusted) mean total QALYs over 26 weeks.  IP generated 
slightly more QALYs than either of the advice groups, and AA slightly more than AR, but the magnitude of 
QALY gains from AA relative to AR and from IP relative to UCP were small (0.006 and 0.019 extra QALYs 
respectively). 
Incremental cost-utility analysis  
For the primary analysis (complete data, NHS health care perspective, baseline adjusted), relative to AR, AA 
generated a mean of 0.0095 (95% CI −0.0140 to 0.0344) more QALYs per participant at an additional cost of 
£87.87 (95%CI −14.33 to 200.83), yielding an incremental cost effectiveness ratio of £9,256 (Table 4).  Relative 
to UCP, IP generated a mean of 0.0143 (95% CI −0.0077 to 0.0354) more QALYs per participant and a cost 
saving of -£14.22 (95% CI −87.14 to 66.01). Based on the results of the non-parametric bootstrap, AA was 
found to have a 71.3% chance of being the preferred strategy at a ceiling ratio of £20,000 per QALY gained 
(see Figure 1a, and 75.6% at £30,000 per QALY gained).  IP was cost-effective across a range of thresholds 
(see Figure 1b which illustrates ceiling ratios up to £60,000 per QALY gained).  In the secondary analysis 
(complete data, NHS and private health care perspective, baseline adjusted), for AA vs AR the incremental 
mean QALY difference was 0.0095 (95% CI -0.0140 to 0.0344) with a mean cost difference of £124.69 (-19.13 
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to 266.21). For IP vs UCP, the incremental mean QALY difference was 0.0143 (95% CI -0.0077 to 0.0354) 
with a mean cost difference of -£39.02 (-124.28 to 55.92).  The ICERs were £13,134 for AA vs AR, and UCP 
was dominated by IP, which means the comparator (IP) was more effective (more QALYs) and less expensive 
than the intervention against which it was compared (UCP). 
Sensitivity analysis  
Re-running the main analysis with multiple imputation (MI) for missing cost and QALY data indicated that the 
cost-effectiveness results were somewhat sensitive to missing data, but the conclusions essentially remained 
unchanged (Table 4).  The imputed data suggested smaller non-significant cost advantages of AR over AA, 
(reduced by around 62%), and of IP over UCP. Mean cost differences were £33.06 (95% CI 1.14 to 65.38) and 
-£18.39 (95% CI -109.57 to 85.97) for AA vs AR and IP vs UCP respectively. The mean difference in QALYs 
was lower using the imputed data compared to the complete case analysis (0.0001 (95% CI -0.0119 to 0.0110) 
for AA vs AR; 0.0088 (−0.0082 to 0.0338) for IP vs UCP).  
To assess the impact on the main results of cost “outliers”, we excluded the 6 participants (4, 1, and 1 from 
AA, AR, and IP respectively) whose health care costs exceeded £1,000.  This led to AA having an ICER of 
£2,053 compared with AR. IP remained costing less and gained more QALYS compared with UCP. 
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DISCUSSION 
Study findings 
This economic evaluation supports and extends the clinical evaluation of the ARM trial reported in an earlier 
paper.8 For decision-makers applying a WTP threshold of £20,000 per QALY gained to judge the cost-
effectiveness of competing interventions, there was less difference in costs and QALYs between the competing 
strategies, and assuming patients prefer to be seen earlier rather than later, IP would be the preferred strategy 
(vs UCP). If patients need to wait then AA (£9,256 per QALY) was a more cost-effective strategy than AR. 
The results from the clinical effectiveness trial using mDASH as the primary clinical outcome are consistent 
with these findings on QALYs in terms of direction, although the magnitude of QALYs is slightly smaller.  Two 
possible explanations might be offered as to why the QALYs outcomes diverge somewhat from the primary 
clinical outcome. First, in the main clinical paper8, the main difference was in the proportion of participants 
reporting full recovery (i.e. mDASH = 0) at 26 weeks (i.e. determined only at the time of the final follow-up), 
which was 12.9% (95% CI: 2.3%, 23.7%) higher amongst people receiving AA compared with AR.  In addition, 
there was a smaller non-significant difference in mDASH between IP and UCP (-2.8%, 95% CI: -11.3%, 6.5%). 
The QALYs on the other hand, were assessed over six months of follow-up, which is perhaps reflected in the 
very small difference in QALYs reported here. Assuming an EQ-5D health utility of 1.0 = perfect health at 26 
weeks to be equivalent to fully recovered/no disability,  the increase in probability of full recovery as measured 
by EQ-5D was 18.9% (0.3774 with AA and 0.1887 with AR). Thus, we know from the main results paper8, that 
the differences between AA and AR in DASH =0 only become apparent at the final follow-up, and so we might 
reasonably expect any differences in QALYs to be smaller. A second reason might be due to the fact that the 
main economic analysis was restricted to a relatively small subset of participants with complete data (around 
36% and a potential limitation of the current analysis), although these results were generally shown to be 
robust after conducting a secondary analysis with imputation for missing data. Moreover, in relation to the 
analysis of the primary clinical outcome, when this was restricted to participants with complete data, the results 
were similar.  So, the missing data are unlikely to have caused any major discrepancies in either outcomes. 
Limitations 
Our economic analysis suggests small non-significant differences in costs and QALYs between the 
competing strategies for clinical management.  The level of uncertainty associated with the estimated 
differences is however large, and this points to a need for further larger studies. Also, future studies might 
assess how potential variations in subgroups of patients (e.g. in terms of chronicity of their condition), as well 
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as using a longer study time horizon than the (≥ 6 months) impact on costs, effects, and cost-effectiveness of 
physiotherapy management strategies in arm pain.   
 
Higher health care costs with AA were driven by more community physiotherapy visits and a range of visits 
to private providers. It is possible that the advice to remain active led some respondents to seek extra 
information or reassurance that the particular forms of activity that they were undertaking or planning were 
safe.  Further, the content of advice leaflets may have had some influence on care-seeking behaviour in the 
AA group: the leaflet stated “Sometimes, of course, people need additional help. If things are not improving 
in a few weeks, you may need treatment.  A physiotherapist can use massage and exercises to help improve 
the pain and get you going. If you get some relief, it may be repeated a number of times while you recover, if 
you get no relief a different type of treatment may be tried”.  The advice to rest leaflet did not contain this 
statement.  We did not collect data during the trial on how people engaged with the advice leaflet, so these 
explanations can only be speculative. 
 
Generalisability 
While IP was not associated with superior outcomes in terms of QALY gains, compared to physiotherapy 
delivered after a median of 45-47 days on a waiting list, there was a non-significant reduction in costs.  This 
is consistent with earlier research, which may suggest that our results generalise to other populations. For 
example, previously published research on back pain points to potential cost savings associated with early 
intervention.18-21  For instance, in a large national (employer-sponsored health plans) database study in the 
US involving 32,070 patients with a new primary care lower back pain consultation,19 initiation of early 
physical therapy (referred to as physical therapy within 14 days of the index consultation) as compared with 
delayed physical therapy (occurring between 15 and 90 days from the index consultation) was associated 
with reduced risk of surgery, injections, physician visits, opioid use, and advanced imaging during an 18 
month follow-up period, along with a corresponding reduction in overall lower back pain-related medical 
costs.  Total annual health care costs for patients receiving early care from a physical therapist were on 
average US $2,736.23 lower per patient.  Similar results were obtained in an even larger study (753,450 
patients with a primary care visit for lower back pain) carried out in 2015 by the same authors.18  The precise 
mechanisms regarding explanations for these changes in health care costs were not however explored in 
these studies, (e.g. behavioural versus physiological versus institutional, or a combination of these factors), 
and there remains a need for further study to understand the reasons for the cost differences.. 
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Conclusions 
Decision-makers may judge that a strategy of advice to remain active is preferable to one that encourages 
advice to rest, as there is a greater probability of full recovery.  Further, immediate physiotherapy appears a 
preferable strategy, on the grounds that it may deliver some cost savings, and is likely to align better with 
patient preference. To reduce decision uncertainty, we recommend that future estimates of the cost-
effectiveness of arm pain management strategies be based on larger sample sizes. 
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Figure Legends 
 
Figure 1 Cost-effectiveness planes and cost-effectiveness acceptability curves for ARM pain trial treatment 
groups (complete case dataset, NHS perspective). Cost-effectiveness planes were based on 1000 bootstrap 
cost-effect pairs (adjusted for baseline age, gender, work status, modified dash, EQ-5D health utility score 
and NHS cost). AA, advice active; AR, advice to rest; IP, immediate physiotherapy; UCP, usual care 
(waiting-list) physiotherapy; QALY, quality adjusted life year. 
 
Supplementary Figure S1 The Arm Pain Trial – Patient Flow Diagram8 
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a) AA - AR 
  
b) IP - UCP 
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Table 1 Unit costs applied to value health care resource use (£, 2013/14 UK prices) 
Resource Unit Source  Basis of estimate 
Cost 
(£) 
NHS health care resource use      
GP Surgery     
GP Visit Curtis 11.7 minutes surgery consultation 46 
Practice nurse Visit Curtis  Surgery consultation 15.5 minutes 14 
Community physiotherapist Visit Curtis assumes visit lasts 30 minutes 18 
Other community  Visit Curtis Assumes cost of physiotherapy 18 
CT – Chiropractor Visit Curtis Assumes cost of physiotherapy 18 
CT – Osteopath Visit Curtis Assumes cost of physiotherapy 18 
CT – Other Visit Curtis Assumes cost of physiotherapy 18 
Outpatient clinic – Rheumatology Visit NHS Reference Costs WF01A Non-admitted Face to Face Follow-up Attendance, Rheumatology, 410,  WF01B 
Non-admitted Face to Face First, 410, Rheumatology (mean over these two categories) 
168 
Outpatient – Orthopaedics Visit NHS Reference Costs WF01A Non-admitted Face to Face Attendance, First attendance, Trauma & Orthopaedics, 
110, WF01B, Non-admitted Face to Face Attendance, Single, 410, Trauma & Orthopaedics 
(mean cost over these two categories) 
113 
Outpatient – Other Visit NHS Reference Costs WF01A Non-admitted Face to Face Attendance, Follow-up, 191, Pain Management, WF01B 
Non-admitted Face to Face Attendance, First, Pain Management (mean cost over these two 
categories) 
154 
Other HCP –  Physiotherapist Visit NHS Reference Costs WF01B Non-admitted Face to Face Attendance, First, 650, Physiotherapy. WF01A Non-
admitted Face to Face Attendance, Follow-up, 650, Physiotherapy. (mean cost over these 
two categories) 
47 
Other HCP –  Other Visit NHS Reference Costs Assumes cost of a physiotherapy attendance 47 
Emergency admission Day NHS Reference Costs AB04Z Pain Procedures, Accident & Emergency, 181  (mean cost per patient over 
Intermediate and Minor categories) 
561 
Planned (elective) admission Day NHS Reference Costs HD26G Musculoskeletal Signs and Symptoms, Pain Management, 191 (mean cost over CC 
Score 0-3 and 4-7 categories) 
341 
Private (non-NHS) treatment resource use     
HCP – Doctor Visit UK Beam Trial Mean cost of private specialist visit - uprated 177 
HCP – Physiotherapist Visit UK Beam Trial Mean cost of private physiotherapist outpatient attendance – uprated. 112 
HCP – Chiropractor Visit Wonderling et al 2004 Mean cost of a private visit chiropractor or osteopath – uprated  38 
HCP – Osteopath Visit Wonderling et al 2004 Mean cost of a private visit chiropractor or osteopath – uprated 38 
HCP – Other (e.g. acupuncturist) Visit UK Beam Trial Assumes mean cost of a private physiotherapist outpatient attendance – uprated. 112 
HCP – Other  Visit UK Beam Trial Assumes mean cost of a private physiotherapist outpatient attendance – uprated. 112 
Hospital admission Day UK Beam Trial Mean cost of private hospital admission/ day uprated  584 
GP = General practitioner; HCP = Health care professional; CT=Complementary therapist 
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Table 2 Mean resource use and costs per patient over 26 weeks follow-up (complete case analysis n=193) 
Resource use item Active advice (AA), n=53 Advice to rest (AR), n=60 Immediate physiotherapy (IP), n=80 
Resource 
users,  
n (%)1  
Mean 
resource 
use (SD) 
Mean cost, 
£ (SD) 
Resource 
users,  
n (%)1  
Mean 
resource 
use (SD) 
Mean cost, 
£ (SD) 
Resource,  
users, n 
(%)1  
Mean 
resource 
use (SD) 
Mean cost, 
£ (SD) 
NHS 
Primary 
care  
 
Patient advice booklet1 53 (100) 1 (-) £1·09 (-) 60 (100) 1 (-) £1·09 (-) na na na 
GP visits 14 (26) 0·70 (1·58) £32·11 (£72·5) 21 (35) 0·67  (1·32) £30·67 (£60·88) 19 (24) 0·54 (1·38) £24·73 (£63·36) 
Practice nurse visits 1 (2) 0·02 (0·14) £0·26 (£1·92) 6 (10) 0·13 (0·43) £1·87 (£6·03) 1 (1) 0·03 (0·22) £0·35 (£3·13) 
Community physiotherapist visits 32 (60) 2·25 (2·73) £40·42 (£49·16) 36 (60) 1·40 (1·60) £25·2 (£28·74) 35 (44) 1·26 (1·93) £22·73 (£34·69) 
Other community visits 6 (11) 0·11 (0·32) £2·04 (£5·76) 6 (10) 0·13 (0·47) £2·40 (£8·43) 6 (8) 0·14 (0·57) £2·48 (£10·22) 
CT visits – Chiropractor 0 - - 0 - - 0 - - 
CT visits – Osteopath 1 (2) 0·02 (0·14) £0·34 (£2·47) 0 - - 0 - - 
CT visits – Other 12 (27) 0·83 (1·92) £14·94 (£34·54) 3 (5) 0·12 (0·58) £2·1 (£10·53) 4 (5) 0·13 (0·60) £2·25 (£10·89) 
Total NHS primary care costs (unadjusted)   £90.11 (£105.18)   £62.23 (£71.79)   £52.53 (£80.67) 
NHS 
hospital 
care 
Outpatient visits – Rheumatology 3 (6) 0·11 (0·58) £19·02 (£96·96) 1 (2) 0·02 (0·13) £2·8 (£21·69) 3 (4) 0·05 (0·27) £8·4 (£45·52) 
Outpatient visits – Orthopaedics 3 (6) 0·11 (0.47) £12·79 (£57·72) 3 (5) 0·12 (0·52) £13·18 (£59·18) 6 (8) 0·09 (0·33) £9·89 (£36·82) 
Outpatient visits – Other 5 (9) 0·15 (0·53) £23·25 (£82·14) 7 (12) 0·17 (0·53) £25·67 (£81·03) 5 (6) 0·08 (0·31) £11·55 (£47·61) 
Other HCP visits – Physiotherapist 36 (68) 2·98 (3·38) £140·11 (£158·71) 48 (80) 2·32 (2·57) £108·88 (£120·99) 52 (65) 2·56 (2·71) £120·44 (£127·53) 
Other HCP visits – Other 3 (6) 0·11 (0·51) £5·32 (£23·79) 4 (5) 0·10 (0·40) £4·7 (£18·76) 7 (9) 0·13 (0·46) £5·88 (£21·64) 
Emergency admission days 0  - - 0 - - 0 -  
Planned (elective) admission days 3 (6) 0·06 (0·23) £19·30 (£79·55) 1 (2) 0·02 (0·13) £5·68 (£44·02) 2 (3) 0·04 (0·25) £12.79 (£84·82) 
Total NHS hospital costs (unadjusted)   £219.79 (£266.36)   £160.92 (£178.47)   £168.94 (£187.44) 
Total NHS costs (unadjusted) 53  £309.91 (£321.45) 60  £223.15 (£225.39) 80  £221.46 (£220.54) 
Private 
(non-NHS) 
treatment  
HCP consultations – Doctor 2 (4) 0·09 (0·56) £16·70 (£99·79) 2 (3) 0·05 (0·29) £8·85 (£50·75) 1 (1) 0·03 (0·22) £4·43 (£39·58) 
HCP consultations – Physiotherapist 8 (15) 0·47 (1·49) £52·83 (£166·71) 7 (12) 0·2 (0·61) £22·4 (£67·77) 2 (3) 0·11 (0·81) £12·6 (£90·86) 
HCP consultations – Chiropractor 0  - - 0 - - 0 - - 
HCP consultations – Osteopath 1 (2) 0·02 (0.14) £0·72 (£5·22) 0 - - 0 - - 
HCP consultations – Other 2 (4) 0·23 (1·17) £8·60 (£44·49) 0 - - 2 (3) 0·05 (0·31) £1·9 (£11·94) 
Hospital admission days 0 - - 0 - - 0 - - 
Total private treatment costs (unadjusted) 53 £78.85 (£194.35) 60 £31.25 (£97.22) 80 £18.93 (£102.31) 
Total NHS + private costs (unadjusted) 53 £388·75 (£422·39) 60 £254·4 (266·65) 80 £240.39 (£253.28) 
1 The advice booklet cost is not included in the comparison of differences in total costs for advice active versus advice rest, but is included in the comparison of differences in immediate physiotherapy versus usual care 
(waiting-list) physiotherapy 
 GP, general practitioner; CT, Complementary therapist; HCP, Health care professional; AA, Active Advice; AR, Advice to rest; IP. Immediate physiotherapy; UCP, Usual care (waiting-list) physiotherapy 
 Note. Total NHS costs for usual care (waiting-list) physiotherapy (UCP) = £263.84 (276.82). 
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Table 3 Mean EQ-5D health utility scores and QALYs over 26 weeks follow-up (complete case analysis n=193)  
EQ-5D utility (SD) Active advice (AA), n=53 Advice to rest (AR), n=60 Immediate physiotherapy (IP), n=80 
Baseline 0.699 (0·231) 0·709 (0·188) 0·714 (0·156) 
6 weeks 0·711 (0·270) 0·694 (0·244) 0·759 (0·205) 
13 weeks 0·740 (0·258) 0·739 (0·149) 0·792 (0·214) 
26 weeks 0·808 (0·247) 0·768 (0·195) 0·796 (0·228) 
QALYs over 26 weeks 0·372 (0·111) 0·366 (0·077) 0·388 (0·089) 
QALYs, quality-adjusted life-years; IP, Immediate physiotherapy; UCP, Usual care (waiting-list) physiotherapy.  Note. Total QALYs for Usual care (waiting-list) 
physiotherapy = 0.369 (0.094) 
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Table 4 Adjusted1 mean incremental costs, incremental QALYs, and incremental cost-effectiveness ratio over 26 weeks (complete case analysis n=193) 
Analysis Incremental mean cost, £ (95% CI)2,3 Incremental mean QALYs (95% CI)2,4 Mean ICER (£/QALY) 
 
 
AA v AR 87.87 (-14.33 to  200.83) 0.0095 (-0.0140 to 0.0344) 9,256 
IP v UCP -14.22 (−87.14 to 66.01) 0.0143 (-0.0077 to 0.0354) IP dominant (cost per QALY gained < 0) 
Secondary (NHS + private perspective)    
AA v AR 124.69 (-19.13 to 266.21) 0.0095 (-0.0140 to 0.0344) 13,134 
IP v UCP -39.02 (-124.28 to 55.92) 0.0143 (-0.0077 to 0.0354) IP dominant (cost per QALY gained < 0) 
SA: Imputed dataset (NHS)    
AA v AR 33.06 (1.14 to 65.38) 0.0001 (-0.0119 to 0.0110) 264,049 
IP v UCP -18.39 (−109.57 to 85.97) 0.0088 (-0.0082 to 0.0338) IP dominant (cost per QALY gained < 0) 
SA: excluding cost “outliers” (NHS)    
AA v AR 36.51 (-54.11 to  127.27) 0.0178 (-0.0050 to 0.0412) 2,053 
IP v UCP -2.38 (-61.25 to 58.62) 0.0109 (-0.0097 to 0.0323) IP dominant (cost per QALY gained < 0) 
1 Adjusted for baseline differences (age, gender, work status (full or part-time/ other), modified dash (=0 no disability/>=1 disability), EQ-5D health utility score, and baseline NHS cost). 
2 Bootstrapped non-parametric 95% confidence interval (2.5th/97.5th percentile). 
3 Generalised linear model with γ distribution and log link function to estimate incremental costs and generalised linear model with gauss distribution and identity link function to estimate incremental QALYs 
(complete cases). 
 QALYs, quality-adjusted life-years; IP, Immediate physiotherapy; UCP, usual care (waiting-list) physiotherapy; ICER, incremental cost-effectiveness ratio; WTP, willingness-to-pay; CE, cost effectiveness. AA, 
Active Advice; AR, Advice to rest; IP.  
 
